U.S. markets closed
  • S&P 500

    -64.76 (-1.72%)
  • Dow 30

    -486.27 (-1.62%)
  • Nasdaq

    -198.88 (-1.80%)
  • Russell 2000

    -42.72 (-2.48%)
  • Crude Oil

    -4.06 (-4.86%)
  • Gold

    -29.40 (-1.75%)
  • Silver

    -0.78 (-3.99%)

    -0.0145 (-1.47%)
  • 10-Yr Bond

    -0.0110 (-0.30%)

    -0.0398 (-3.54%)

    +0.9950 (+0.70%)

    +357.69 (+1.91%)
  • CMC Crypto 200

    -9.92 (-2.23%)
  • FTSE 100

    -140.92 (-1.97%)
  • Nikkei 225

    -159.30 (-0.58%)

Nanomerics Joins Royal Society of Chemistry Broadening Horizons Programme

·3 min read

London, United Kingdom September 22nd, 2022. Nanomerics Ltd., a private speciality pharmaceutical company, specialising in developing drugs based on its Molecular Envelope Technology, today announced that the company was joining the Royal Society of Chemistry's Broadening Horizons Programme. The funded initiative is aimed at diversifying personnel within the UK chemical sciences industrial sector and follows on from the Royal Society of Chemistry's research, which revealed that Black and minority ethnic chemists were leaving the industry, due to a lack of progression and other factors. Nanomerics' Chief Scientific Officer, Professor Ijeoma F. Uchegbu, said, "I am delighted that Nanomerics will be offering a paid internship to underrepresented ethnic minority chemists as part of the Royal Society of Chemistry's bold Broadening Horizon programme". The BBC News article may be accessed here.

Nanomerics is focused on developing innovative medicines using its Molecular Envelope Technology (MET). For example, Nanomerics' Sunlight Trial will examine the safety and tolerability of OC134 in human volunteers in 2022. OC134 is indicated for the treatment of severe allergic conjunctivitis.

Nanomerics is using its Molecular Envelope Technology to create formulations that address areas of unmet medical need. The targeted drug deposition, achieved with Nanomerics' MET will enable lower doses to be used, could lead to improved response rates and reduced side effects; effectively improving the therapeutic index of multiple assets.

About Nanomerics

Nanomerics Ltd, Sunday, July 24, 2022, Press release picture
Nanomerics Ltd, Sunday, July 24, 2022, Press release picture

Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include OC134 for the treatment of allergic conjunctivitis and OC137 for the treatment of non-infectious posterior uveitis. Additionally, a number of pharmaceutical product candidates have already been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX), e.g. Envelta™, which is being developed as a pain therapeutic and AnQlar™, which is being developed as an anti-viral nasal spray. For more information, please visit www.nanomerics.com.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Nanomerics cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Forward-looking statements reflect our analysis only on their stated date, and Nanomerics takes no obligation to update or revise these statements except as may be required by law.

View source version on accesswire.com: